Intellia Therapeutics (NTLA) to Release Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.21) per share for the quarter.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Down 7.3 %

Intellia Therapeutics stock traded down $1.83 during trading hours on Friday, reaching $23.31. 114,221 shares of the company’s stock were exchanged, compared to its average volume of 1,556,908. The firm has a market capitalization of $2.25 billion, a PE ratio of -4.54 and a beta of 1.81. The firm’s 50 day simple moving average is $24.33 and its 200 day simple moving average is $25.44. Intellia Therapeutics has a twelve month low of $19.37 and a twelve month high of $40.98.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 27th. BMO Capital Markets upped their price target on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Citigroup reduced their price objective on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.